RxDoctor Payments Data

James Botts, MD

Hospitalist · Spartanburg, SCNPI 1700827995

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Among hospitalist clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,291in general payments, 2019–2025

Across 69 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$190
  • Pfizer$175
  • Johnson & Johnson$123
  • Novartis$111
  • Boehringer Ingelheim$100
  • AbbVie$84
  • plus $508 from 15 others

What the payments were for

  • Food & beverage$1,291100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,291 in reported general payments places this provider in the 90th percentile of 398 hospitalist providers in South Carolina.

See all hospitalist providers in South Carolina

Medicare billing

Part B allowed, 2024
$71,728
Medicare patients
220
Services billed
685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban46$22,541
VraylarCariprazine Hcl11$7,744
MyrbetriqMirabegron18$5,736
BelsomraSuvorexant12$5,681
Breo ElliptaFluticasone/Vilanterol12$4,635
Potassium Chloride38$820
Levetiracetam30$765
Sucralfate11$760
Levothyroxine Sodium86$644
Pantoprazole Sodium48$396
Midodrine Hcl16$390
Omeprazole57$389
Duloxetine Hcl25$338
Quetiapine Fumarate29$337
Cefdinir25$278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$175$22,54146 claims
AbbVieVraylar$84$7,74411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 398 hospitalist providers in South Carolina.

Other hospitalist in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →